GANGAGEN
GangaGen, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutic proteins targeting infectious diseases in areas of high unmet need such as MRSA and other drug resistant bacteria. Using a proprietary platform, GangaGen is developing highly-specific therapeutic proteins called ectolysins to target clinically meaningful types of bacteria. The company’s lead ectolysin, P128, is a recombinant protein that binds to and kills Staphylococcus, including methicillin-resistant strains of S. aureus (MRSA).
GANGAGEN
Social Links:
Industry:
Biotechnology
Founded:
2000-01-01
Address:
Bangalore, Karnataka, India
Country:
India
Website Url:
http://www.gangagen.com
Total Employee:
11+
Status:
Active
Contact:
+1-650-8569642
Email Addresses:
[email protected]
Total Funding:
2.5 M USD
Similar Organizations
Avistone Pharmaceuticals
Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.
ConserV Bioscience
ConserV Bioscience is a clinical-stage biotechnology company focused on developing vaccines.
Lytica Therapeutics
Lytica Therapeutics, Inc. is a biotechnology company focused on developing novel peptide therapeutics.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
Current Employees Featured
Founder
Investors List
CARB-X
CARB-X investment in Grant - GangaGen
Official Site Inspections
http://www.gangagen.com
- Host name: 17.51.180.107.host.secureserver.net
- IP address: 107.180.51.17
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "GangaGen"
Home - GangaGen
[...]Read More... from HomeSee details»
About - GangaGen
GangaGen advanced it’s candidate compound into human clinical trials for the decolonization of Methicillin Resistant Staphylococcus aureus from human …See details»
Board of Directors - GangaGen
GangaGen Biotechnologies Pvt. Ltd., India (GBPL) Dr. T. S. Balganesh President, GBPL and Member, Board of Directors, GBPL View Bio. ... He and his wife Eliza established the ATEL …See details»
GangaGen - Crunchbase Company Profile & Funding
GangaGen, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutic proteins targeting infectious diseases in areas of high unmet …See details»
GangaGen - 2025 Company Profile, Funding & Competitors - Tracxn
GangaGen is an acquired company based in Bengaluru (India), founded in 2000. It operates as a Develop drugs for the prevention and treatment of bacterial infections that are resistant to …See details»
GangaGen Biotechnologies | LinkedIn
GangaGen Biotechnologies | 3,254 followers on LinkedIn. Pioneering the Development of Novel Ectolysins and Bacteriocins against Drug-resistant Bacteria | GangaGen, is a biotechnology company focused on the …See details»
GangaGen :: Pioneering the battle against drug-resistant bacteria
GangaGen, Inc. was founded in India in 2000 and incorporated in the US in 2001 by Dr. J. Ramachandran, with the aim to develop novel therapies for treating antibiotic-resistant …See details»
Gangagen Company Profile | Management and Employees List
Gangagen Profile and History. GangaGen Biotechnologies (GBPL) is a wholly owned subsidiary of Bactoclear Holdings, Singapore. The company is designing and developing novel Protein …See details»
GangaGen - Funding, Financials, Valuation & Investors - Crunchbase
GangaGen is a clinical-stage biotechnology company focused on developing novel therapeutic proteins. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log …See details»
Management - GangaGen
Prior to joining GangaGen in 2004, Mr. Sukumar was responsible for the fermentation process development of therapeutic proteins in yeast expression systems at Bigtec Private Limited, Bangalore. Mr. Sukumar has a Bachelor’s …See details»
GangaGen :: Pioneering the battle against drug-resistant bacteria
Dr. Ramachandran is a member of the Indian Academy of Sciences (elected in 1988). He was a member of the Scientific and Technical Advisory Committee on Tropical Diseases Research …See details»
GangaGen Biotechnologies - Devex
GangaGen Biotechnologies Private Limited, India (GBPL), is a biologics company specialized in discovering, designing and developing novel therapies for treating serious bacterial infections.See details»
GangaGen - Crunchbase Company Profile & Funding
GangaGen is a clinical-stage biotechnology company focused on developing novel therapeutic proteinsSee details»
GangaGen :: Pioneering the battle against drug-resistant bacteria
Pioneering the Development of Novel Ectolysins against Drug-resistant Bacteria . Pioneering the Development of Novel Ectolysins against Drug-resistant BacteriaSee details»
GangaGen, Inc. - VentureRadar
GangaGen is developing ectolysins to treat drug resistant bacteria. GangaGen, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutic proteins targeting …See details»
Gangagen Company Profile - Office Locations, Competitors ... - Craft
Gangagen is a biotechnology company focused on the development of products for the prevention and treatment of bacterial infections. Using a proprietary platform, it provides …See details»
Contact - GangaGen
[...]Read More... from ContactSee details»
GangaGen 2025 Company Profile: Valuation, Funding & Investors
GangaGen General Information Description. Developer of engineering novel treatments designed to prevent bacterial infections that are resistant to antibiotics. The company's treatment is a …See details»
GangaGen - Contacts, Employees, Board Members, Advisors
GangaGen is a clinical-stage biotechnology company focused on developing novel therapeutic proteins. New. Resources. Advanced Search ... Experience the new Crunchbase, powered by …See details»
Careers - GangaGen
GangaGen is an innovative company focused on the discovery and development of therapeutic proteins and phages for the treatment of serious bacterial infections. Interested candidates …See details»